37.79
0.60 (1.61%)
| Penutupan Terdahulu | 37.19 |
| Buka | 37.49 |
| Jumlah Dagangan | 28,332 |
| Purata Dagangan (3B) | 148,288 |
| Modal Pasaran | 597,729,728 |
| Harga / Jualan (P/S) | 8.11 |
| Harga / Buku (P/B) | 3.03 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Keuntungan | -124.15% |
| Margin Operasi (TTM) | -105.54% |
| EPS Cair (TTM) | -6.20 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 62.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.13% |
| Nisbah Semasa (MRQ) | 2.05 |
| Aliran Tunai Operasi (OCF TTM) | -56.19 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -16.50 M |
| Pulangan Atas Aset (ROA TTM) | -25.49% |
| Pulangan Atas Ekuiti (ROE TTM) | -133.65% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Assembly Biosciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -5.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 0.5 |
| Purata | 0.00 |
|
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 39.25% |
| % Dimiliki oleh Institusi | 12.77% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| B Group, Inc. | 30 Sep 2025 | 175,706 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (HC Wainwright & Co., 32.31%) | Beli |
| Median | 39.50 (4.53%) | |
| Rendah | 38.00 (JMP Securities, 0.56%) | Beli |
| Purata | 41.75 (10.48%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 28.53 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Mizuho | 20 Nov 2025 | 40.00 (5.85%) | Beli | 36.73 |
| HC Wainwright & Co. | 14 Oct 2025 | 50.00 (32.31%) | Beli | 28.39 |
| JMP Securities | 24 Sep 2025 | 38.00 (0.56%) | Beli | 25.66 |
| Guggenheim | 08 Sep 2025 | 39.00 (3.20%) | Beli | 23.32 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |